Search results
Results From The WOW.Com Content Network
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. [ 3 ] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan ...
Inhalable insulin. Inhalable insulin is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed. [1] In general inhaled insulins have been more rapidly absorbed than subcutaneous injected insulin, with faster peak concentration in serum and more rapid metabolism. [2]
Alkermes plc Reports Third Quarter Fiscal 2013 Financial Results — Company Improves Guidance for Fiscal 2013, Driven by Stronger Revenues and Lower Expenses — — Third Quarter Non-GAAP ...
Together with cash on hand, the $375 million in new senior secured bank debt borrowed by Alkermes, Inc. will be used to retire the balance of its $450 million of existing senior secured bank debt ...
Alkermes plc Reports Second Quarter Fiscal 2013 Financial Results — Company Improves Guidance for Fiscal 2013, With $25 Million Increase in Non-GAAP Net Income Guidance to a Range of $120 ...
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. [3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation ...
Biomedical engineering. Institutions. Harvard University. Website. davidideas.com. David A. Edwards (born April 6, 1961) is an American biomedical engineer, and the founder of Sensory Cloud. [1][2] He was the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University. [3][4] Edwards designs inhalable medicines ...
From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating ...